Bristol Raises Guidance on Demand for Eliquis, New Drugs
Bristol Myers Squibb Co. raised its 2024 earnings guidance after reporting better-than-expected revenue and profit, fueled by demand for the blood-thinner Eliquis and several newer treatments.Adjusted ...
Bristol Myers earnings beat expectations, driven by sales of older drugs
Bristol Myers Squibb reported a higher-than-expected third-quarter profit on Thursday, citing strong sales of established ...
Bristol Myers Squibb Boosts 2024 Outlook On Strong Demand For Blood Thinner Med, New Drugs Drive Q3 Profit
On Thursday, Bristol Myers Squibb & Co (NYSE:BMY) posted third-quarter revenues of $11.89 billion, beating the consensus of ...
Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs
The increase came from Eliquis and the company's so-called Growth ... offset by leukemia treatment Sprycel, which is facing ...